Cited by 2,953Angiogenesis and VEGF in CancerCancer Cells and MetastasisLymphatic System and Diseases

The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.

Modes of resistance to anti-angiogenic therapy

Open access

Bergers, Gabriele, Hanahan, Douglas·2008·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. However, in both preclinical and clinical settings, the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results: evasive resistance, an adaptation to circumvent the specific angiogenic blockade; and intrinsic or pre-existing indifference. Multiple mechanisms can be invoked in different tumour contexts to manifest both evasive and intrinsic resistance, motivating assessment of their prevalence and importance and in turn the design of pharmacological strategies that confer enduring anti-angiogenic therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc2442

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citation
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“Endothelial and pericyte progenitors differentiate into endothelial cells, which form the inner lining of blood vessel walls, or pericytes, the cells that envelop blood vessels, respectivel”
Background
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citation
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
Background
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,551
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,413 · cited 1×
“By contrast, pro-angiogenic monocytes, such as tumour-associated macrophage”
Background
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,104 · cited 1×
“aspx?CdrID=39762">paclitaxel extended progression-free survival (but not overall survival”
Background
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 1×
“Evidence that low oxygen tension triggers the recruitment of BMDCs stems from observations in experimentally induced ischaemic tissue, wherein endothelial progenitors and other CXCR4 + BMDCs are recruited, in part through increases in HIF1α and its downstream effectors SDF1α (a CXCR4 ligand) and VEGF itsel”
Background
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · cited 1×
“Thus, virtually every VEGFR kinase inhibitor has an attendant variety of additional moderate-to-high affinity kinase targets in the 'kinome”
Background
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“Moreover, two VEGF pathway inhibitors (the RNA aptamer pegaptanib and a Fab derivative of bevacizumab) have been approved for treating the angiogenic (wet) form of macular degeneratio”
Background
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,299
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 1×
“Additional reviews, in this Focus on targeting angiogenesi”
Background
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Self-citation
The role of pericytes in blood-vessel formation and maintenance
Bergers, G., & Song, S. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000232 · Cited by 1,584
Self-citation
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
Self-citation
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,273
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Self-citation
HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
Du, R., Lu, K. V., Petritsch, C. K., Liu, P., Ganß, R., Passegue, E. A., Song, H., VandenBerg, S. R., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,166
Self-citation
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,125 · cited 1×
“— exert their functions as vascular modulators by expressing a variety of cytokines, growth factors and proteases without being physically part of the vasculatur”
Background
Endothelial-pericyte interactions in angiogenesis
Gerhardt, H., & Betsholtz, C. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0745-x · Cited by 1,086 · cited 1×
“A growing body of evidence indicates that pericytes, the periendothelial support cells of the microvasculatur”
Background
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050 · cited 1×
“Additional reviews, in this Focus on targeting angiogenesi”
Background
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 1,013
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. F. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 1,006
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · cited 1×
“Moreover, two VEGF pathway inhibitors (the RNA aptamer pegaptanib and a Fab derivative of bevacizumab) have been approved for treating the angiogenic (wet) form of macular degeneratio”
Background
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R. B., Norberg, S. M., O’Brien, S., Sennino, B., Nakahara, T., Yao, V., Inai, T., Brooks, P. C., Freimark, B. D., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 814
Bevacizumab for recurrent malignant gliomas
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R. A., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 809
Cellular abnormalities of blood vessels as targets in cancer
Bałuk, P., Hashizume, H., & McDonald, D. M. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 782 · cited 1×
“Notably, the morphology of these surviving tumour vessels is readily distinguishable from the typically dilated tumour vessels of untreated animals, which are, by contrast, variably covered with less closely associated pericyte”
Background
A microenvironmental model of carcinogenesis
Gatenby, R. A., & Gillies, R. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2255 · Cited by 741 · cited 1×
“This seemingly preordained return to growth and progression in the face of ostensibly potent angiogenesis inhibitors conflicts with the widely accepted proposition that angiogenesis is an essential capability for the manifestation of lethal cance”
Background
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X., Yao, J. J., Blanchard, D., Bais, C., Peale, F. V., Jr., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 652
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
Hattori, K., Heissig, B., Wu, Y. L., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Böhlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 636
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631 · cited 1×
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
Background
Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells.
Orlidge, A., & D'Amore, P. A. (1987) · The Journal of Cell Biology · doi:10.1083/jcb.105.3.1455 · Cited by 614 · cited 1×
“In addition, pericytes are capable of attenuating the proliferation rate of endothelial cell”
Background
Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms
Erber, R., Thurnher, A., Katsen, A. D., Groth, G., Kerger, H., Hammes, H., Menger, M. D., Ullrich, A., & Vajkoczy, P. (2003) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 607
The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis
Petit, I., Jin, D. K., & Rafii, S. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.05.007 · Cited by 605
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1971 · Cited by 586 · cited 1×
“The fact that receptor tyrosine kinase inhibitors can transiently increase plasma levels of pro-angiogenic factors such as VEGF and placental growth factor (PlGF, also known as PGF ) has been previously recognized in the clinic, and even proposed as a predictive biomarker for tumour respons”
Background
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A., Hicklin, D. J., Chaplin, D. J., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 568
PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival
Song, S., Ewald, A. J., Stallcup, W. B., Werb, Z., & Bergers, G. (2005) · Nature Cell Biology · doi:10.1038/ncb1288 · Cited by 551
Self-citation
Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand‐Rosenberg, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.284 · Cited by 537
SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells
FALCO, E. D., Porcelli, D., Torella, A. R., Straino, S., Iachininoto, M. G., Orlandi, A., Truffa, S., Biglioli, P., Napolitano, M., Capogrossi, M. C., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4423 · Cited by 519
Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 510
A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer
Pietras, K., & Hanahan, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Self-citation
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470 · cited 1×
“Indeed, some tumour endothelial cells have been reported to be aneuploi”
Background
Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
Pietras, K., Pahler, J. C., Bergers, G., & Hanahan, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050019 · Cited by 452
Self-citation
Pericytes: Cell Biology and Pathology
Allt, G., & Lawrenson, J. G. (2001) · Cells Tissues Organs · doi:10.1159/000047855 · Cited by 451 · cited 1×
“A growing body of evidence indicates that pericytes, the periendothelial support cells of the microvasculatur”
Background
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 443
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 428
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
Saltz, L. B., Lenz, H., Kindler, H. L., Höchster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gönen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 427 · cited 1×
“The clinical achievements with bevacizumab, sunitinib and sorafenib constitute a milestone event for the field of angiogenesis research, eliciting survival benefits in many aggressive tumours, but there is a sobering addendum: these VEGF pathway inhibitors are failing to produce enduring clinical responses in most pat…”
Background
The semaphorins: versatile regulators of tumour progression and tumour angiogenesis
Neufeld, G., & Kessler, O. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2404 · Cited by 427 · cited 1×
“Additional reviews, in this Focus on targeting angiogenesi”
Background
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
Self-citation
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
Mizukami, Y., Jo, W., Duerr, E., Gala, M. K., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., Zukerberg, L. R., Kohgo, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1294 · Cited by 407
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
Kunkel, P., Ulbricht, U., Böhlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., Westphal, M., & Lamszus, K. (2001) · PubMed · Cited by 398
Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival
Darland, D. C., Massingham, L. J., Smith, S. R., Piek, E., Saint‐Geniez, M., & D'Amore, P. A. (2003) · Developmental Biology · doi:10.1016/j.ydbio.2003.08.015 · Cited by 383 · cited 1×
“and that tumour pericytes, which are juxtacrine to endothelial cells, express appreciable levels of VEGF and potentially other factors that support endothelial cell surviva”
Background
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 368 · cited 1×
“Such propositions, however, may require refinement or reconsideration in light of recent experiments that revealed increased levels of pro-angiogenic factors in the circulation of sunitinib-treated control (non-tumour-bearing) mice, implicating a systemic endocrine response to inhibition of VEGF and PDGF signalling in…”
Background
A cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 368
Pericytes limit tumor cell metastasis
Xian, X. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25705 · Cited by 345 · cited 1×
“In one study, genetic disruptions of pericyte coverage elicited increased metastasis in the Rip1–Tag2 pancreatic islet tumour mode”
Background
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera‐Troise, I., & Yancopoulos, G. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2130 · Cited by 297
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 262 · cited 1×
“One recent study suggests that hypoxia determines survival outcome in bevacizumab-treated GBM patient”
Background
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Narayana, A., Kelly, P., Golfinos, J. G., Parker, E. C., Johnson, G., Knopp, E. A., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., et al. (2008) · Journal of neurosurgery · doi:10.3171/2008.4.17492 · Cited by 242
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria‐Petit, A., Klement, G. L., Coomber, B. L., & Rak, J. W. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 238
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Oraefo, E., Schrag, D., Hurwitz, H. I., McLeod, H. L., Mulcahy, M. F., Schilsky, R. L., & Goldberg, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4508 · Cited by 235
Antiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway
Tan, C., de Noronha, R. G., Roecker, A. J., Pyrzyńska, B., Khwaja, F. W., Zhang, Z., Zhang, H., Teng, Q., Nicholson, A. C., Giannakakou, P., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.605.65.2 · Cited by 226
What brings pericytes to tumor vessels?
Jain, R. K., & Booth, M. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320087 · Cited by 178
Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes
Aghi, M. K., Cohen, K. S., Klein, R. J., Scadden, D. T., & Chiocca, E. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3759 · Cited by 175 · cited 1×
“In a study of neovascularization in glioblastoma multiforme (GBM), a tumour type characterized by extensive hypoxia and necrosis, HIF1α was found to promote angiogenesis and tumour growth by inducing recruitment of various pro-angiogenic bone marrow-derived CD45 + (also known as PTPRC + ) myeloid cells, including subp…”
Background
The HIF pathway in cancer
Maxwell, P. H. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.001 · Cited by 171 · cited 1×
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
Background
Differential diagnosis of pancreatic tumors using ultrasound contrast imaging
Sofuni, A., Iijima, H., Moriyasu, F., Nakayama, D., Shimizu, M., Nakamura, K., Itokawa, F., & Itoi, T. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1578-z · Cited by 166 · cited 1×
“Pancreatic ductal adenocarcinoma (PDAC) may display another class of pre-existing resistance, manifest as a tumour type that is characteristically hypovascularized with a massive (largely avascular) desmoplastic stroma”
Background
Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors
Fernando, N. T., Koch, M., Rothrock, C., Gollogly, L. K., D'Amore, P. A., Ryeom, S. W., & Yoon, S. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4126 · Cited by 162 · cited 1×
“, evasive resistance is largely indirect: alternative ways to sustain tumour growth are activated but the specific therapeutic target of the anti-angiogenic drug remains inhibite”
Background
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A. S., Emmenegger, U., Ma, L., Thorpe, P. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 161 · cited 1×
“The fact that receptor tyrosine kinase inhibitors can transiently increase plasma levels of pro-angiogenic factors such as VEGF and placental growth factor (PlGF, also known as PGF ) has been previously recognized in the clinic, and even proposed as a predictive biomarker for tumour respons”
Background
Control of angiogenesis by the pericyte: Molecular mechanisms and significance
Hirschi, K. K., & D'Amore, P. A. (1997) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-9006-9_18 · Cited by 161
The genetics of pancreatic cancer
Cowgill, S. M., & Muscarella, P. (2003) · The American Journal of Surgery · doi:10.1016/s0002-9610(03)00226-5 · Cited by 156 · cited 1×
“For example, ∼75% of PDACs carry inactivating mutations in the TP53 tumour suppressor gen”
Background
Genetic and hypoxic regulation of angiogenesis in gliomas
Kaur, B., Tan, C., Brat, D. J., & Meir, E. G. V. (2004) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-2752-5 · Cited by 152 · cited 1×
“These diffusely growing tumours do not form lesions with a prominent neovasculature containing proliferative endothelial cell”
Background
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Sessa, C., Guibal, A., Conte, G. D., & Rüegg, C. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1150 · Cited by 150
What brings pericytes to tumor vessels?
Jain, R. K., & Booth, M. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20087 · Cited by 143
A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Sarker, D., Molife, R., Evans, T. R. J., Hardie, M., Marriott, C., Bützberger, P., Morrison, R., Fox, J. A., Heise, C. C., Louie, S. G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1466 · Cited by 138
Heterogeneous Vascular Dependence of Tumor Cell Populations
Yu, J., Rak, J. W., Carmeliet, P., Nagy, A., Kerbel, R. S., & Coomber, B. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64083-7 · Cited by 134 · cited 1×
“, loss of which in another tumour type has been shown to improve survival in hypoxic conditions, including ones induced by angiogenesis inhibitio”
Background
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases
Lesslie, D. P., Summy, J. M., Parikh, N. U., Fan, F., Trevino, J., Sawyer, T. K., Metcalf, C. A., Shakespeare, W. C., Hicklin, D. J., Ellis, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603143 · Cited by 126
Delta-like 4/Notch Signaling and Its Therapeutic Implications
Yan, M., & Plowman, G. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1393 · Cited by 121
Genetic alterations in pancreatic carcinoma.
Schneider, G., & Schmid, R. M. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-15 · Cited by 121 · cited 1×
“For example, ∼75% of PDACs carry inactivating mutations in the TP53 tumour suppressor gen”
Background
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Wang, X., Le, P., Liang, C., Chan, J., Kiewlich, D., Miller, T. M., Harris, D., Sun, L., Rice, A. G., Vasile, S., et al. (2003) · PubMed · Cited by 114
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
Gorre, M. E., & Sawyers, C. L. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00007 · Cited by 113
Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors
Sun, J., Wang, D.-A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Baldini, L., Coppola, D., Hamilton, A. D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208391 · Cited by 108
Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy
Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 94
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
GLADEBENDER, J., COONEY, E., KANDEL, J., & Yamashiro, D. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.09.001 · Cited by 87
Molecular and cellular biomarkers for angiogenesis in clinical oncology
Bertolini, F., Mancuso, P., Shaked, Y., & Kerbel, R. S. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.011 · Cited by 83 · cited 1×
“The fact that receptor tyrosine kinase inhibitors can transiently increase plasma levels of pro-angiogenic factors such as VEGF and placental growth factor (PlGF, also known as PGF ) has been previously recognized in the clinic, and even proposed as a predictive biomarker for tumour respons”
Background
Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation
Kadenhe‐Chiweshe, A. V., Papa, J. C., McCrudden, K. W., Frischer, J. S., Bae, J.-O., Huang, J., Fisher, J. C., Lefkowitch, J. H., Feirt, N. M., Rudge, J. S., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0101 · Cited by 75 · cited 1×
“, evasive resistance is largely indirect: alternative ways to sustain tumour growth are activated but the specific therapeutic target of the anti-angiogenic drug remains inhibite”
Background
Can tumor angiogenesis be inhibited without resistance?
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7311-3_7 · Cited by 69
Antiangiogenic Therapy for Cancer: An Update
Shojaei, F., & Ferrara, N. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31815a7b69 · Cited by 68 · cited 1×
“The clinical achievements with bevacizumab, sunitinib and sorafenib constitute a milestone event for the field of angiogenesis research, eliciting survival benefits in many aggressive tumours, but there is a sobering addendum: these VEGF pathway inhibitors are failing to produce enduring clinical responses in most pat…”
Background
Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents
O'Connor, R. A., CLYNES, M. M., Dowling, P., O’Donovan, N., & O’Driscoll, L. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.805 · Cited by 63 · cited 1×
“In contradistinction to traditional concepts of drug resistance being acquired by mutational alteration of the gene encoding a drug target or by alterations in drug uptake and efflu”
Background
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
Marty, M. E., & Pivot, X. B. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.005 · Cited by 60
Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed
Kerbel, R. S. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.016 · Cited by 58
Pegaptanib sodium for the treatment of age-related macular degeneration
Apte, R. S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.3.499 · Cited by 48 · cited 1×
“Moreover, two VEGF pathway inhibitors (the RNA aptamer pegaptanib and a Fab derivative of bevacizumab) have been approved for treating the angiogenic (wet) form of macular degeneratio”
Monoclonal antibodies against components of the IGF system for cancer treatment.
Feng, Y., & Dimitrov, D. S. (2008) · PubMed · Cited by 27
A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
von Pawel, J., Kaiser, R., Eschbach, C., Štefanič, M., Love, J., Gatzemeier, U., & Reck, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7635 · Cited by 19
A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
Garrett, C. R., Siu, L. L., El-Khoueiry, A. B., Buter, J., Rocha‐Lima, C., Marshall, J. L., Kollia, G. D., Velasquez, L., Syed, S. S., & Feltquate, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4111 · Cited by 17
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
Garrett, C. R., Siu, L. L., Giaccone, G., El-Khoueiry, A. B., Marshall, J. L., LoRusso, P. M., Velasquez, L., Kollia, G. D., He, P., & Feltquate, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14018 · Cited by 5

Flagged first, then by citations

Research works printed but not linked: 1

Berger, M. S. & Wilson, C. B. The Gliomas (W.B. Saunders, Philadelphia, 1999).

Sorted by citations

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
“…where potent angiogenesis inhibitors succeed in suppressing this hallmark capability, tumors adapt and shift from a dependence upon continuing angiogenesis to heightening the activity of another instead—invasiveness and metastasis (Azam et al., 2010: Ebos et al., 2009; Bergers and Hanahan, 2008).”
Self-citation
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
“Aberrant FGF signalling promotes tumour angiogenesis and mediates the escape of tumour vascularization from VEGF- or epidermal growth factor receptor (EGFR)-inhibitor treatmen”
Background
Malignant Gliomas in Adults
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,890
“Increasing evidence suggests that anti-VEGF therapy may increase the tendency of tumor cells to co-opt existing blood vessels, resulting in an invasive nonenhancing phenotype.(52-54) Unlike the Macdonald Criteria, which do not take into account progressive nonenhancing disease, the new response assessment will conside…”
Background
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
“The translational promise of this first targeted therapy against the tumour microenvironment, however, is somewhat tempered by emerging instances of resistance to anti-angiogenic therap”
Background

See all 2,953

Authors: Bergers, G., & Hanahan, D.
Affiliations: University of California, San Francisco (US)
ORCID: Bergers, Gabriele
Hanahan, Douglas
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2008-08
Volume: 8
Issue: 8
Pages: 592-603
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2442
PMC: PMC2874834
OpenAlex: W2017322644
Cited by: 2,953
References: 101
Citations by year: 2026: 70 · 2025: 77 · 2024: 97 · 2023: 130 · 2022: 95 · 2021: 172 · 2020: 133 · 2019: 152 · 2018: 148 · 2017: 202 · 2016: 217 · 2015: 228 · 2014: 241 · 2013: 248 · 2012: 215
FWCI: 13.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA099948)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords: anti-angiogenic therapy, drug resistance, vascular endothelial growth factor, VEGF signaling, tumor angiogenesis, intrinsic resistance, combination therapy
MeSH terms: Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Modes of resistance to anti-angiogenic therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks